Insider buying last 90 days
No open-market insider purchases were filed for AZTA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AZTA insider filing, plotted on the chart in Gekko.Open AZTA in Gekko
NASDAQ: AZTA
Azenta (AZTA) Stock Analysis & Forecast
Oct 12 close
$37.77+0.05 (+0.1%)
Gekko Brief
AI summaryOct 12 closeAzenta's stock has been under pressure this week following the resignation of President and CEO John P. Marotta, a development tied to a 12% drop and to subsequent securities class action investigations announced by Rosen Law Firm. Separately, the company approved a restructuring plan within its Multiomics segment, closing three North American laboratory sites and cutting jobs as part of an $11 million to $13 million restructuring effort. On the analyst side, Argus raised its price target for Azenta to $41.00, while other firms including Needham and Evercore ISI Group have reiterated Buy and Outperform ratings.
Azenta closed at $37.77, little changed on the day, with the price sitting above both its 50-day average of $33.73 and its 200-day average of $28.28. The GekkoIndex reading of 55.3 places the stock in the Neutral zone. The current price stands 27.7% above Gekko Fair Value of $29.57.
The next earnings report is scheduled for 20 November 2026, 39 days away, placing it outside a typical 20-trading-day holding window. No insider, Congress or unusual options activity appears in their respective windows. Seasonality from this point in the calendar has averaged a 5.9% move over the next 20 trading days across 5 years, rising in 3 of them. The consensus among 3 analysts stands at 2 buys and 1 hold, with a consensus target of $37 implying a -2% upside from current levels.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Azenta price vs fair value
Close $37.77200-day averageGekko Fair Value $29.57
Azenta quick facts
- Market cap
- $1.74B
- P/E ratio
- —
- Forward P/E
- 29.1
- EPS, TTM
- −$2.47
- Revenue, TTM
- $613.8M
- Profit margin
- -20%
- Dividend yield
- —
- Beta
- 1.52
- Volume
- 944,767 avg 1.18M
- 1-year return
- +19.0%
- Typical daily move
- ±6.7%
- Typical 20-day move
- ±9.3%
- 50-day average
- $33.73
- 200-day average
- $28.28
- Next earnings
- Nov 20
- Shares outstanding
- 43.81M
Azenta swing-trade checklist
Azenta scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $37.77 is above the 50-day ($33.73) and 200-day ($28.28) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
55.3, Neutral
Reading 55.3 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
27.7% above
Price is 27.7% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 39 days
Next report Nov 20, 2026, 39 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.9% on average
From this point in the calendar, the next 20 trading days averaged +5.9% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Azenta stock chart and price history
Azenta closed at $37.77 on Oct 12, 2026, +19.0% over the past year, inside a 52-week range of $15.93 to $46.41.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +22.4%
- 3 months
- +48.5%
- 6 months
- +61.9%
- 1 year
- +19.0%
The full AZTA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AZTA in Gekko
Follow Azenta through every session
Put AZTA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AZTA in GekkoFree for 7 days. No credit card required.
About Azenta
Azenta provides tools and services built around life science samples, covering everything from locating and handling specimens to keeping them safely preserved over time. The company works with research organizations handling biological and chemical materials and is particularly associated with systems that support sample management throughout the research process.
The business runs through two segments. One builds automated cold storage systems along with the instruments, consumables and preparation equipment that researchers use to manage samples during their work. The other delivers services such as sample banking, cold chain logistics, genomic sequencing, gene synthesis, lab processing and analysis, and biospecimen sourcing, supported by informatics tools. Customers span pharmaceutical and biotechnology companies, biorepositories, and academic and private research institutions, and the company operates across North America, Europe, Asia Pacific and other regions.
Azenta traces back to 1978 under the name Brooks Automation, Inc., adopting its current name in December 2021. It is headquartered in Chelmsford, Massachusetts, and its shares are listed on the NASDAQ under the ticker AZTA.
- Listed
- NASDAQ
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- azenta.com
Azenta GekkoIndex: the smart money zone
Azenta’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.3, in the Neutral zone, up 24.6 points over five sessions.
55.3Neutral
Up 24.6 points over five sessions, from the Selling zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 60 | +0.4% | −0.8% | ||
| Accumulation | 233 | −0.4% | −2.2% | ||
| Neutral (current zone) | 369 | −0.1% | +0.8% | ||
| Distribution | 19 | +0.3% | −13.1% | ||
| Selling | 1 | Too few readings yet | |||
Average AZTA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the AZTA price, zone by zone.Track AZTA in Gekko
Is Azenta stock overvalued? Gekko Fair Value
Azenta trades 27.7% above Gekko Fair Value of $29.57, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Azenta shares are worth, recalculated every trading day.
$29.57
Gekko Fair Value, Oct 10, 2026
27.7% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open AZTA in Gekko
Azenta insider and Congress trading
No open-market insider purchases were filed for Azenta, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in AZTA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for AZTA, plotted on the chart in Gekko.Open AZTA in Gekko
Buybacks
Azenta has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $50.05M
- As a share of market cap
- 2.87%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds AZTA.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Azenta earnings: next date and track record
Azenta reports on Nov 20, 2026 (39 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 20, 2026
39 days away
- EPS estimate
- $0.11
- Revenue estimate
- $160.3M
5 of 8reports beat the EPS estimate
±13.1%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, May 6, 2026 AI summary
- What they said
- Azenta's Q2 FY2026 earnings call covered disappointing quarterly results with organic revenue down 3% and adjusted EBITDA margin of 5.4%, below expectations. Management emphasized execution-related issues within their control—notably in North America Multiomics and automated and cryogenic store systems—while Europe and APAC showed strength, particularly in Multiomics and sample repository solutions. Non-GAAP EPS was a loss of $0.04; GAAP included significant goodwill impairments ($112.4M for Multiomics, $36.6M for Sample Management Solutions) and an additional $6M noncash loss related to assets held for sale (B Medical Systems). Management discussed actions: commercial and operational restructuring, partial restructuring yielding $7M annualized savings ($3M in-year), reorganization of automated stores, bringing in new leadership (Trey) for gene synthesis, and maintaining growth investments (~$20M) tied to the LRP. They are cautious on North American demand and competitive pressure but optimistic about recurring revenue durability, UK Biocentre acquisition progress, and long-term market opportunities in biorepositories, gene synthesis, and automated solutions.
- Guidance
- Updated fiscal 2026 guidance: revenue down low-end of range ~ down 2% (organic) to +1% at high-end (reflecting continued North America softness in Multiomics); management emphasized a conservative posture and derisked plan paired with cost actions. They expect partial benefit from $7M annualized savings (approx. $3M in current year). If B Medical reconsolidation were required, it would occur at quarter end (June 30).
- Risks flagged
- Risk factors cited include execution-related shortfalls (commercial/human capital gaps), intensified competition (especially in gene synthesis in North America), constrained customer spending/research funding in North America, prolonged cautious demand environment, quality issues and remediation delays in automated stores (3 remaining stores), potential reconsolidation risk of B Medical if transaction doesn't close, goodwill impairments driven by stock price decline and macro/geopolitical uncertainty.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 6, 2026 | −$0.04 est $0.15 | $144.8M est $148.3M | −24.5% |
| Feb 4, 2026 | $0.09 est $0.11 | $148.6M est $147.1M | −24.5% |
| Nov 21, 2025 | $0.21 est $0.20 | $159.2M est $156.2M | +22.3% |
| Aug 5, 2025 | $0.19 est $0.13 | $143.9M est $156.7M | −12.4% |
| May 7, 2025 | $0.05 est $0.09 | $143.4M est $149.3M | +9.0% |
| Feb 5, 2025 | $0.08 est $0.06 | $147.5M est $141.3M | +4.0% |
| Nov 12, 2024 | $0.18 est $0.11 | $656.3M est $169.6M | −2.9% |
| Aug 6, 2024 | $0.16 est $0.07 | $172.8M est $171.1M | −4.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Azenta stock forecast and analyst price targets
Analysts’ average 12-month price target for Azenta is $37.00, −2.0% from the last close, from 3 firms rating the stock in the last 90 days.
$37.00consensus 12-month target, −2.0% from the last close
Now $37.77Avg $37.00
Low $33High $37
Each firm’s latest rating in the last 90 days: 3 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 14 | Needham | $37 | −2.0% |
| Aug 6 | Evercore ISI | $35 | −7.3% |
| Aug 5 | TD Cowen | $33 | −12.6% |
| Aug 5 | Needham | $37 | −2.0% |
+0.8%average 20-day move after past Neutral readings
+5.9%average move over the next 20 trading days in the last 5 years
±6.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Azenta seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Azenta averaged +5.9% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.4% | 4 of 5 |
| Next 10 trading days | +4.2% | 3 of 5 |
| Next 15 trading days | +3.3% | 3 of 5 |
| Next 20 trading days | +5.9% | 3 of 5 |
| Next 30 trading days | +17.8% | 5 of 5 |
For scale, AZTA’s typical 20-trading-day move in either direction is about 9.3%.
Azenta market cap and key statistics
Azenta’s market cap is $1.74B and revenue of $613.8M over the last twelve months.
Valuation
- Market cap
- $1.74B
- Forward P/E
- 29.1
- EPS, TTM
- −$2.47
- Gekko Fair Value
- $29.57
Trading
- Volume
- 944,767
- Avg volume, 20 days
- 1.18M
- 52-week high
- $46.41
- 52-week low
- $15.93
- Shares outstanding
- 43.81M
Financials
- Revenue, TTM
- $613.8M
- Profit margin
- -20%
- Return on equity
- -7%
- Quarterly earnings growth, YoY
- +8,778.0%
Risk and income
- Beta
- 1.52
- Typical daily move
- ±6.7%
- Typical 20-day move
- ±9.3%
Azenta stock news this week
Coverage of Azenta this week reads negative: 2 positive, 1 neutral and 3 negative headlines.
- Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewsWire, Oct 12
- Azenta, Inc. (AZTA) Stock ForecastsYahoo! Finance Canada, Oct 11
- Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTAGuruFocus, Oct 10
- Azenta, Inc. Investor News: If You Have Suffered Losses inGlobeNewswire, Oct 10
- ROSEN, A LEADING NATIONAL FIRM, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTANewsfile Corp, Oct 9
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTANewsfile Corp, Oct 8
Azenta peers
Azenta’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 2.5% below |
| GHGuardant Health | Accumulation | 10.0% below |
| SOLVSolventum | Accumulation | 20.5% below |
| BTSGBrightSpring Health Services | Neutral | 2.8% above |
| EHCEncompass Health | Neutral | 7.3% above |
| DVADaVita | Neutral | 14.6% below |
A peer links to its own page where one exists.
Azenta stock FAQ
What is Azenta’s market cap?
Azenta’s market cap is $1.74B at the Oct 12, 2026 close of $37.77, with 43.81M shares outstanding.
What is the Azenta stock forecast?
The consensus analyst 12-month price target for Azenta is $37.00, −2.0% from the last close. Of the 3 firms that rated the stock in the last 90 days, 2 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Azenta stock overvalued or undervalued?
On Gekko’s estimate Azenta is overvalued: the Oct 12, 2026 close of $37.77 is 27.7% above Gekko Fair Value of $29.57. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Azenta report earnings next?
Azenta is expected to report on Nov 20, 2026 (39 days away). Analysts expect earnings of $0.11 per share on revenue of $160.3M. Azenta beat the earnings estimate in 5 of its last 8 reports, moving 13.1% on average across the report.
What is Azenta’s 52-week high and low?
Azenta’s 52-week high is $46.41 and its 52-week low is $15.93; it closed at $37.77 on Oct 12, 2026, +19.0% over the past year. Over the last five years the shares peaked at $124.79 on Nov 9, 2021.
Is Azenta stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Azenta the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.